Anastasi S - Search Results

1

Feedback inhibition by RALT controls signal output by the ErbB network.

Anastasi S, Fiorentino L, Fiorini M, Fraioli R, Sala G, Castellani L, Alemà S, Alimandi M, Segatto O. Anastasi S, et al. Oncogene. 2003 Jul 3;22(27):4221-34. doi: 10.1038/sj.onc.1206516. Oncogene. 2003. PMID: 12833145

2

The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity.

Anastasi S, Baietti MF, Frosi Y, Alemà S, Segatto O. Anastasi S, et al. Oncogene. 2007 Dec 13;26(57):7833-46. doi: 10.1038/sj.onc.1210590. Epub 2007 Jun 18. Oncogene. 2007. PMID: 17599051

3

Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.

Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S, Lucini F, Ingvarsson S, Segatto O. Anastasi S, et al. Oncogene. 2005 Jun 30;24(28):4540-8. doi: 10.1038/sj.onc.1208658. Oncogene. 2005. PMID: 15856022

4

A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation.

Frosi Y, Anastasi S, Ballarò C, Varsano G, Castellani L, Maspero E, Polo S, Alemà S, Segatto O. Frosi Y, et al. Among authors: anastasi s. J Cell Biol. 2010 May 3;189(3):557-71. doi: 10.1083/jcb.201002032. Epub 2010 Apr 26. J Cell Biol. 2010. PMID: 20421427 Free PMC article.

5

Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors.

Segatto O, Anastasi S, Alemà S. Segatto O, et al. Among authors: anastasi s. J Cell Sci. 2011 Jun 1;124(Pt 11):1785-93. doi: 10.1242/jcs.083303. J Cell Sci. 2011. PMID: 21576352 Review.

6

A pervasive role for MIG6 in restraining cell proliferation.

Anastasi S, Castellani L, Alemà S, Segatto O. Anastasi S, et al. Cell Death Differ. 2014 Mar;21(3):345-7. doi: 10.1038/cdd.2013.182. Epub 2013 Dec 20. Cell Death Differ. 2014. PMID: 24362438 Free PMC article. No abstract available.

7

Regulation of the ErbB network by the MIG6 feedback loop in physiology, tumor suppression and responses to oncogene-targeted therapeutics.

Anastasi S, Lamberti D, Alemà S, Segatto O. Anastasi S, et al. Semin Cell Dev Biol. 2016 Feb;50:115-24. doi: 10.1016/j.semcdb.2015.10.001. Epub 2015 Oct 9. Semin Cell Dev Biol. 2016. PMID: 26456277 Review.

8

Lack of Evidence that CYTH2/ARNO Functions as a Direct Intracellular EGFR Activator.

Anastasi S, Zhu SJ, Ballarò C, Manca S, Lamberti D, Wang LJ, Alemà S, Yun CH, Segatto O. Anastasi S, et al. Cell. 2016 May 19;165(5):1031-1034. doi: 10.1016/j.cell.2016.05.009. Cell. 2016. PMID: 27203102 Free article. No abstract available.

9

HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma.

Lamberti D, Cristinziano G, Porru M, Leonetti C, Egan JB, Shi CX, Buglioni S, Amoreo CA, Castellani L, Borad MJ, Alemà S, Anastasi S, Segatto O. Lamberti D, et al. Among authors: anastasi s. Hepatology. 2019 Jan;69(1):131-142. doi: 10.1002/hep.30127. Epub 2018 Dec 14. Hepatology. 2019. PMID: 30067876

10

Making sense of Cbp/p300 loss of function mutations in skin tumorigenesis.

Anastasi S, Alemà S, Segatto O. Anastasi S, et al. J Pathol. 2020 Jan;250(1):3-6. doi: 10.1002/path.5336. Epub 2019 Oct 9. J Pathol. 2020. PMID: 31397888

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

48 results

Search Page

Filters